Last reviewed · How we verify
NCT07358520
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
Phase 4 trial testing Huaier Granule in Proteinuria in 40 participants. Not yet recruiting.
28 January 2027
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 28 January 2026 |
| Primary completion | 28 January 2027 |
| Estimated completion | 28 January 2028 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Huaier Granule — full drug profile →
- Anlotinib and Bevacizumab — full drug profile →
Conditions studied
- Proteinuria — all drugs for Proteinuria →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Proteinuria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07358520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Huaier Granule
Trials testing the same drug.
- NCT07355361 — Huaier Granule and Proteinuria · Phase 2 · not yet recruiting
- NCT07197853 — Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA No · Phase 3 · not yet recruiting
- NCT05673824 — Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. · Phase 2 · completed
- NCT04790305 — Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer · Phase 4 · recruiting
- NCT04291053 — The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 · Phase 2, PHASE3 · unknown
Other recruiting trials for Proteinuria
Currently open trials in the same condition.
- NCT07030894 — Nefecon and Ambrisentan in IgA Nephropathy · Phase 4 · recruiting
- NCT06923709 — Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease · Phase 2 · recruiting
- NCT06162546 — ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank · recruiting
- NCT05457283 — A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor · Phase 3 · recruiting
- NCT05196035 — A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, a · Phase 3 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07358520 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07358520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing